Detalhe da pesquisa
1.
OX40/OX40 ligand and its role in precision immune oncology.
Cancer Metastasis Rev
; 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38526805
2.
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer.
BMC Med
; 22(1): 74, 2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38369520
3.
Carcinoma of unknown primary: Molecular tumor board-based therapy.
CA Cancer J Clin
; 72(6): 510-523, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36006378
4.
Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer.
Int J Mol Sci
; 25(9)2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38731962
5.
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Invest New Drugs
; 40(1): 99-105, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34468905
6.
Cutaneous perivascular epithelioid cell tumor (PEComa): case report and world literature review of clinical and molecular characteristics.
Dermatol Online J
; 28(1)2022 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499412
7.
Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers.
Int J Cancer
; 148(3): 702-712, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32700810
8.
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Int J Cancer
; 148(11): 2839-2847, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33497479
9.
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Cancer
; 127(3): 391-402, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33119140
10.
KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
Oncologist
; 26(4): e530-e536, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33528846
11.
Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.
Oncologist
; 26(9): 787-796, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34080753
12.
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Oncologist
; 26(7): e1104-e1109, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742489
13.
Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting.
Int J Cancer
; 146(2): 566-576, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31199507
14.
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies.
Int J Cancer
; 146(12): 3450-3460, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31782524
15.
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Oncologist
; 25(2): 94-98, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043794
16.
Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience.
Oncologist
; 25(11): e1803-e1806, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949172
17.
Identification of targets for prostate cancer immunotherapy.
Prostate
; 79(5): 498-505, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30614027
18.
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Cancer
; 125(3): 463-472, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30383888
19.
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
Br J Cancer
; 118(11): 1419-1424, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695765
20.
Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
Oncologist
; 23(2): 171-178, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29038235